Otilimab - GlaxoSmithKline

Drug Profile

Otilimab - GlaxoSmithKline

Alternative Names: GSK-3196165; GSK165; MOR-103

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Developer GlaxoSmithKline; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • No development reported Inflammation
  • Discontinued Multiple sclerosis; Osteoarthritis

Most Recent Events

  • 21 Oct 2018 Efficacy and adverse events data from a phase II trial in Rheumatoid arthritis released by GlaxoSmithKline
  • 01 Aug 2018 Discontinued - Phase-II for Osteoarthritis in Germany, Netherlands, United Kingdom, Poland and USA (SC)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top